AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
February 29 2024 - 4:49AM
AB Science will host a live webcast on Monday March 4, 2024, from
6.30pm to 7.30pm CET
PRESS RELEASE
AB SCIENCE WILL HOST A LIVE WEBCAST ON
MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET
Paris, 29 February, 2024, 11.30am CET
AB Science SA (Euronext –
FR0010557264 – AB) will host a live webcast on Monday March 4,
2024, from 6.30pm to 7.30pm CET.
The agenda of this live webcast will be to provide status and
perspective on the following topics:
- Conditional approval of masitinib
in ALS with EMA and Health Canada
- Partnership strategy
- Masitinib platform clinical
development program
- Microtubulin platform development
program
- Intellectual property
The presentation will be followed by a Q&A
session.
Login details for this live webcast will be
provided later.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, inflammatory diseases and viral
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB
ScienceThis press release contains forward-looking
statements. These statements are not historical facts. These
statements include projections and estimates as well as the
assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial
results, events, operations, future services, product development
and their potential or future performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
- Webcast AB Science VEng VF
Ab Science (EU:AB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ab Science (EU:AB)
Historical Stock Chart
From Apr 2023 to Apr 2024
